Early treatment of HER2-amplified brain tumors with targeted NK-92 cells and focused ultrasound improves survival

Neuro-Oncology

Volumn 18, Issue 7, 2016, Pages 974-981

  Alkins, Ryan ^a,b   Burgess, Alison ^a   Kerbel, Robert ^a,b   Wels, Winfried S ^c   Hynynen, Kullervo ^a,b  

^a Sunnybrook Health Sciences Centre   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c INSTITUTE FOR TUMOR BIOLOGY AND EXPERIMENTAL THERAPY   (Germany)

Author keywords

breast cancer; focused ultrasound; immune cell therapy; MRIgFUS

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ANTINEOPLASTIC AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN TUMOR; BREAST CANCER; CELL DIFFERENTIATION; CELL GROWTH; CENTRAL NERVOUS SYSTEM METASTASIS; CONTROLLED STUDY; HIGH INTENSITY FOCUSED ULTRASOUND; HUMAN; HUMAN CELL; LONG TERM SURVIVAL; LONGITUDINAL STUDY; MALE; MICROBUBBLE; NONHUMAN; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RAT; TUMOR GROWTH; BIOLOGICAL THERAPY; BLOOD BRAIN BARRIER; BRAIN NEOPLASMS; BREAST NEOPLASMS; CELL PROLIFERATION; CYTOLOGY; DRUG EFFECTS; METABOLISM; NATURAL KILLER CELL; PATHOLOGY; PROCEDURES; THERAPEUTIC USE; TUMOR CELL LINE; ULTRASOUND THERAPY;

ANTINEOPLASTIC AGENTS; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL- AND TISSUE-BASED THERAPY; HUMANS; KILLER CELLS, NATURAL; MICROBUBBLES; RECEPTOR, ERBB-2; ULTRASONIC THERAPY;

EID: 84977522797     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nov318     Document Type: Article

References (29)

1. Nussbaum ES, Djalilian HR, Cho KH, Hall WA. Brain metastases. Histology, multiplicity, surgery, and survival. Cancer. 1996;78(8): 1781-1788.
2. Hall WA, Djalilian HR, Nussbaum ES, Cho KH. Long-term survival with metastatic cancer to the brain. Med Oncol. 2000;17(4): 279-286.
3. Ohgaki H, Dessen P, Jourde B, et al. Genetic pathways to glioblastoma: a population-based study. Cancer Res. 2004; 64(19):6892-6899.
4. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996.
5. Miralbell R, Mornex F, Greiner R, et al. Accelerated radiotherapy, carbogen, and nicotinamide in glioblastoma multiforme: report of European Organization for Research and Treatment of Cancer trial 22933. J Clin Oncol. 1999;17(10):3143-3149.
6. Patchell RA. The management of brain metastases. Cancer Treat Rev. 2003;29(6):533-540.
7. Abbott NJ, Ronnback L, Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci. 2006; 7(1):41-53.
8. Muldoon LL, Soussain C, Jahnke K, et al. Chemotherapy delivery issues in central nervous system malignancy: a reality check. J Clin Oncol. 2007;25(16):2295-2305.
9. Pardridge WM. The blood-brain barrier: bottleneck in brain drug development. NeuroRx. 2005;2(1):3-14.
10. Kannarkat G, Lasher EE, Schiff D. Neurologic complications of chemotherapy agents. Curr Opin Neurol. 2007;20(6):719-725.
11. Alkins R, Burgess A, Ganguly M, et al. Focused ultrasound delivers targeted immune cells to metastatic brain tumors. Cancer Res. 2013;73(6):1892-1899.
12. Sheikov N, McDannold N, Sharma S, Hynynen K. Effect of focused ultrasound applied with an ultrasound contrast agent on the tight junctional integrity of the brain microvascular endothelium. Ultrasound Med Biol. 2008;34(7):1093-1104.
13. Sheikov N, McDannold N, Vykhodtseva N, Jolesz F, Hynynen K. Cellular mechanisms of the blood-brain barrier opening induced by ultrasound in presence of microbubbles. Ultrasound Med Biol. 2004;30(7):979-989.
14. Deng J, Huang Q, Wang F, et al. The role of caveolin-1 in blood-brain barrier disruption induced by focused ultrasound combined with microbubbles. J Mol Neurosci. 2012;46(3): 677-687.
15. Smyth MJ, Hayakawa Y, Takeda K, Yagita H. New aspects of natural-killer-cell surveillance and therapy of cancer. Nat Rev Cancer. 2002;2(11):850-861.
16. Uherek C, Tonn T, Uherek B, et al. Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction. Blood. 2002; 100(4):1265-1273.
17. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235(4785):177-182.
18. Mineo JF, Bordron A, Baroncini M, et al. Low HER2-expressing glioblastomas are more often secondary to anaplastic transformation of low-grade glioma. J Neurooncol. 2007;85(3): 281-287.
19. Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer. J Clin Oncol. 2004;22(17):3608-3617.
20. Daldrup-Link HE, Meier R, Rudelius M, et al. In vivo tracking of genetically engineered, anti-HER2/neu directed natural killer cells to HER2/neu positive mammary tumors with magnetic resonance imaging. Eur Radiol. 2005;15(1):4-13.
21. McDannold N, Arvanitis CD, Vykhodtseva N, Livingstone MS. Temporary disruption of the blood-brain barrier by use of ultrasound and microbubbles: safety and efficacy evaluation in rhesus macaques. Cancer Res. 2012;72(14):3652-3663.
22. Francia G, Man S, Lee CJ, et al. Comparative impact of trastuzumab and cyclophosphamide on HER-2-positive human breast cancer xenografts. Clin Cancer Res. 2009;15(20):6358-6366.
23. O'Reilly MA, Hynynen K. Blood-brain barrier: real-time feedbackcontrolled focused ultrasound disruption by using an acoustic emissions-based controller. Radiology. 2012;263(1):96-106.
24. Park EJ, Zhang YZ, Vykhodtseva N, McDannold N. Ultrasoundmediated blood-brain/blood-tumor barrier disruption improves outcomes with trastuzumab in a breast cancer brain metastasis model. J Control Release. 2012;163(3):277-284.
25. McDannold N, Clement GT, Black P, Jolesz F, Hynynen K. Transcranial magnetic resonance imaging-guided focused ultrasound surgery of brain tumors: initial findings in 3 patients. Neurosurgery. 2010;66(2):323,32; discussion 332.
26. Ram Z, Cohen ZR, Harnof S, et al. Magnetic resonance imagingguided, high-intensity focused ultrasound for brain tumor therapy. Neurosurgery. 2006;59(5):949,55; discussion 955-6.
27. O'Reilly MA, Huang Y, Hynynen K. The impact of standing wave effects on transcranial focused ultrasound disruption of the blood-brain barrier in a rat model. Phys Med Biol. 2010;55(18): 5251-5267.
28. Gong JH, Maki G, Klingemann HG. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia. 1994;8(4):652-658.
29. Millan J, Hewlett L, Glyn M, Toomre D, Clark P, Ridley AJ. Lymphocyte transcellular migration occurs through recruitment of endothelial ICAM-1 to caveola-and F-actin-rich domains. Nat Cell Biol. 2006;8(2):113-123.